We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
From Apr 2019 to Apr 2024
By Michael Dabaie
AstraZeneca and Merck & Co. said Lynparza demonstrated a long-term progression-free survival benefit versus placebo.
The companies said Lynparza demonstrated a long-term progression-free survival benefit versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who had a complete or partial response following platinum-based chemotherapy.
Five-year follow-up data from the Phase III SOLO-1 trial showed Lynparza reduced the risk of disease progression or death by 67% and improved progression-free survival to a median of 56.0 months versus 13.8 months for placebo.
At five years, 48.3% of patients treated with Lynparza remained free from disease progression versus 20.5% on placebo.
The median duration of treatment with Lynparza was 24.6 months, versus 13.9 months with placebo, the companies said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 18, 2020 10:20 ET (14:20 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
